Dechra Pharmaceuticals PLC (DPHAY) Research

Dechra Pharmaceuticals PLC (DPHAY) is dedicated to the development, manufacturing, regulatory approval, marketing, and sale of veterinary medications and related goods specifically for animal health professionals. The company's operations are structured into three key divisions: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceutical Research and Development. Its extensive product portfolio addresses various animal species: For companion animals like dogs and cats, Dechra offers treatments covering endocrine disorders, dermatological conditions, pain relief, anesthesia, cardiovascular health, and critical care. For livestock, including poultry, pigs, and cattle, the company provides water-soluble antibiotics, avian vaccines, and pain management solutions. Equine offerings primarily focus on lameness and pain management for horses and ponies. Additionally, Dechra supplies specialized nutritional products designed to support cats and dogs with specific therapeutic needs, such as allergies, obesity, and heart or kidney diseases. Beyond its core pharmaceutical activities, the company also distributes veterinary equipment, offers certain financial services, and is involved in the development, regulation, production, and commercialization of crop protection products. Dechra's products reach the market primarily through established networks of wholesalers and distributors. The company's geographical footprint encompasses the United Kingdom, Germany, other European nations, the United States, and various international territories. Dechra Pharmaceuticals PLC was established in 1997 and its corporate headquarters are located in Northwich, United Kingdom.

Open Dechra Pharmaceuticals PLC (DPHAY) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.